Interleukin-6 antagonists for the management of hypertension

被引：9
作者：
Kapoor, Shailendra [1 ]
机构：
[1] Univ Illinois, Dept Family Med, Chicago, IL USA
来源：
HYPERTENSION | 2007年 / 49卷 / 03期
关键词：
D O I：
10.1161/01.HYP.0000257805.64783.d9
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：E18 / E18
页数：1
相关论文
共 4 条
  • [1] Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism
    Luther, James M.
    Gainer, James V.
    Murphey, Laine J.
    Yu, Chang
    Vaughan, Douglas E.
    Morrow, Jason D.
    Brown, Nancy J.
    [J]. HYPERTENSION, 2006, 48 (06) : 1050 - 1057
  • [2] Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    Maini, R. N.
    Taylor, P. C.
    Szechinski, J.
    Pavelka, K.
    Broell, J.
    Balint, G.
    Emery, P.
    Raemen, F.
    Petersen, J.
    Smolen, J.
    Thomson, D.
    Kishimoto, T.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2817 - 2829
  • [3] Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells
    Manfredini, R
    Tenedini, E
    Siena, M
    Tagliafico, E
    Montanari, M
    Grande, A
    Zanocco-Marani, T
    Poligani, C
    Zini, R
    Gemelli, C
    Bergamaschi, A
    Vignudelli, T
    De Rienzo, F
    De Benedetti, PG
    Menziani, MC
    Ferrari, S
    [J]. PEPTIDES, 2003, 24 (08) : 1207 - 1220
  • [4] Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques - Potential implications for inflammation and plaque instability
    Schieffer, B
    Schieffer, E
    Hilfiker-Kleiner, D
    Hilfiker, A
    Kovanen, PT
    Kaartinen, M
    Nussberger, J
    Harringer, W
    Drexler, H
    [J]. CIRCULATION, 2000, 101 (12) : 1372 - 1378
1